Actively Recruiting
Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
Led by Mansoura University · Updated on 2024-12-20
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.
CONDITIONS
Official Title
Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child diagnosed with posterior urethral valve
You will not qualify if you...
- Conditions affecting urinary tract function such as spinal dysraphism, anorectal malformation, or prune belly syndrome
- History of urinary diversion surgery like vesicostomy or cutaneous ureterostomy
- Prior posterior urethral valve ablation treatment at another hospital
- Contraindications to alpha blocker treatment
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mansoura Urology and Nephrology Center
Al Mansurah, Dakahlia Governorate, Egypt, 35511
Actively Recruiting
Research Team
M
Mohamed Hussiny
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here